New England Journal of Medicine December 03, 2015

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

Marc A. Pfeffer, Brian Claggett, Rafael Diaz et al. (ELIXA Investigators)

Bottom Line

In high-risk patients with type 2 diabetes and a recent acute coronary syndrome, the short-acting GLP-1 receptor agonist lixisenatide demonstrated cardiovascular safety by meeting criteria for noninferiority, but it did not provide cardiovascular superiority over placebo.

Key Findings

1. The primary composite outcome (cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina) occurred in 13.4% (406 patients) of the lixisenatide group and 13.2% (399 patients) of the placebo group (HR 1.02; 95% CI, 0.89 to 1.17; P<0.001 for noninferiority, P=0.81 for superiority).

2. There were no significant between-group differences in the rate of hospitalization for heart failure (HR 0.96; 95% CI, 0.75 to 1.23) or all-cause mortality (HR 0.94; 95% CI, 0.78 to 1.13).

3. Lixisenatide did not increase the risk of serious adverse events, severe hypoglycemia, pancreatitis, pancreatic neoplasms, or allergic reactions compared to placebo.

Study Design

Design

RCT

Double-Blind

Sample

6,068

Patients

Duration

25 mo

Median

Setting

Multicenter, global

Population Adults with type 2 diabetes who had a recent acute coronary syndrome (myocardial infarction or hospitalization for unstable angina) within 180 days prior to randomization.

Intervention Lixisenatide (a once-daily, short-acting GLP-1 receptor agonist) injected subcutaneously, added to standard of care.

Comparator Volume-matched subcutaneous placebo injections, added to standard of care.

Outcome A composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina.

Study Limitations

• The median follow-up of 25 months was relatively short, which may have limited the trial's statistical power to detect long-term cardioprotective benefits.

• The cohort exclusively comprised very high-risk patients with a recent acute coronary event (within 180 days), potentially limiting the generalizability of the findings to patients with stable coronary disease or early-stage type 2 diabetes.

• Lixisenatide is a short-acting, prandial GLP-1 receptor agonist; its lack of sustained 24-hour GLP-1 receptor activation may partially explain the absence of the cardiovascular benefit later observed with longer-acting GLP-1 agonists.

Clinical Significance

ELIXA was the first completed cardiovascular outcomes trial (CVOT) for a GLP-1 receptor agonist, proving that lixisenatide is safe to use in patients with type 2 diabetes and high baseline cardiovascular risk. However, unlike longer-acting GLP-1 receptor agonists (such as liraglutide and semaglutide) that subsequently demonstrated cardioprotective superiority in the LEADER and SUSTAIN-6 trials, lixisenatide had a neutral effect on cardiovascular events.

Historical Context

Following the 2007 controversy surrounding the thiazolidinedione rosiglitazone, the FDA issued a 2008 mandate requiring all novel type 2 diabetes medications to undergo rigorous cardiovascular outcomes trials (CVOTs) to definitively rule out excess ischemic cardiovascular risk. ELIXA was the pioneering CVOT for the GLP-1 receptor agonist drug class. While it successfully ruled out excess risk, its neutral efficacy results set the stage for later trials that revealed distinct, within-class differences in the cardioprotective capabilities of longer-acting GLP-1 RAs.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the mechanism of action of GLP-1 receptor agonists like lixisenatide contribute to glycemic control, and why did regulatory agencies mandate large cardiovascular outcome trials (CVOTs) for all new diabetes medications during the era this study was conducted?

Key Response

GLP-1 RAs enhance glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying. Following the rosiglitazone controversy, the FDA issued a 2008 guidance requiring all new type 2 diabetes drugs to definitively rule out unacceptable cardiovascular risk (non-inferiority) via large CVOTs, which is the foundational purpose of the ELIXA trial.

Resident

Given that lixisenatide showed non-inferiority but not superiority for major adverse cardiovascular events (MACE) in the ELIXA trial, how does this influence your choice of GLP-1 receptor agonist when initiating therapy in a diabetic patient with a recent acute coronary syndrome?

Key Response

Residents must recognize that cardiovascular benefit is not a uniform class effect among all GLP-1 RAs. Because lixisenatide did not show CV superiority, a patient with established ASCVD should instead be prescribed an agent with proven MACE reduction (e.g., liraglutide, semaglutide, or dulaglutide) for secondary prevention.

Fellow

Why might a short-acting GLP-1 receptor agonist like lixisenatide fail to show cardiovascular superiority in the ELIXA trial, whereas long-acting agents like liraglutide and semaglutide demonstrated significant MACE reduction in their respective CVOTs?

Key Response

Fellows should understand the pharmacokinetic differences within the class. Short-acting agents primarily lower postprandial glucose via delayed gastric emptying and have 'peak-and-trough' levels, leaving periods without GLP-1 receptor activation. Long-acting agents provide continuous, 24-hour receptor activation, which is hypothesized to be necessary to achieve the sustained anti-inflammatory and anti-atherosclerotic effects that reduce MACE.

Attending

The ELIXA trial uniquely enrolled a highly vulnerable population with a very recent acute coronary syndrome. How should the timing of the index cardiovascular event relative to drug initiation shape our clinical expectations regarding a medication's ability to demonstrate long-term cardiovascular benefit?

Key Response

Attendings should consider the difference between acute plaque instability and long-term atherogenesis. If a drug's primary CV benefit is anti-atherosclerotic (which takes years to manifest), initiating it immediately post-ACS might not prevent early recurrent events driven by acute thrombosis and index plaque healing. This highlights the importance of matching therapeutic mechanisms to the chronicity of the disease state.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The ELIXA trial utilized a composite primary endpoint of cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina. From a methodological standpoint, how does the inclusion of a softer, more subjective endpoint like 'hospitalization for unstable angina' impact statistical power and the interpretation of a non-inferiority design?

Key Response

In non-inferiority trials, adding a soft, frequent endpoint can bias the results toward the null (non-inferiority) if the subjective noise dilutes a true difference in harder, objective endpoints (like CV death or MI). Methodologists must rigorously standardize and adjudicate such endpoints to ensure they do not mask true safety signals or dilute potential superiority signals.

Journal Editor

In reviewing the ELIXA manuscript, how does the relatively short median follow-up time of 25 months affect the validity of the non-inferiority claim, particularly considering that cardiovascular risk and potential off-target effects in post-ACS diabetic patients are highly time-dependent?

Key Response

A critical peer reviewer would flag that a short follow-up might predominantly capture the acute high-risk period where aggressive standard post-ACS care dominates outcomes, potentially masking both longer-term safety signals and delayed anti-atherosclerotic benefits of the intervention. Reviewers must scrutinize whether the accumulation of event rates was sufficient to rule out delayed harm.

Guideline Committee

Based on the ELIXA results demonstrating safety but not efficacy for MACE reduction, how should current ADA/EASD diabetes management guidelines stratify recommendations for specific GLP-1 RAs in patients with established ASCVD, and does lixisenatide merit a different class of recommendation compared to agents proven in the LEADER or SUSTAIN-6 trials?

Key Response

Guidelines now explicitly state that in patients with T2DM and established ASCVD, a GLP-1 RA 'with proven cardiovascular benefit' should be used (Level A evidence). The neutral superiority result of ELIXA means lixisenatide cannot be recommended for CV risk reduction, forcing guidelines to separate individual agents within the GLP-1 RA class rather than endorsing a blanket class-wide assumption of CV benefit.

Clinical Landscape

Noteworthy Related Trials

2016

LEADER Trial

n = 9,340 · NEJM

Tested

Liraglutide up to 1.8 mg daily

Population

T2DM patients with high CV risk

Comparator

Placebo

Endpoint

3-point MACE

Key result: Liraglutide significantly reduced the risk of the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared to placebo.

2016

SUSTAIN-6 Trial

n = 3,297 · NEJM

Tested

Semaglutide 0.5 mg or 1.0 mg weekly

Population

T2DM patients with high CV risk

Comparator

Placebo

Endpoint

3-point MACE

Key result: Semaglutide significantly lowered the rate of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke compared to placebo.

2017

EXSCEL Trial

n = 14,752 · NEJM

Tested

Exenatide extended-release 2 mg weekly

Population

T2DM patients with or without prior CV disease

Comparator

Placebo

Endpoint

3-point MACE

Key result: Exenatide once weekly was noninferior to placebo with respect to safety but did not significantly reduce the incidence of major adverse cardiovascular events.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis